Eduardo Sotomayor, MD, discusses the evolution of CAR T-cell therapy, adverse events that require careful monitoring, and novel strategies under development that may mitigate toxicity and improve T-cell persistence. Read More >>
Blinatumomab (Blincyto) received an 8 to 4 vote from the FDA’s Oncologic Drugs Advisory Committee in favor of an indication for the treatment of MRD-positive B-cell precursor acute lymphoblastic leukemia.
Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now